Alto Neuroscience, Inc. Net Fee Amt
Alto Neuroscience, Inc. (ANRO) had Net Fee Amt of $17.91 thousand as of 2026-04-09, per its S-3 filed 2026-04-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-10
- 2026-04-09: Net Fee Amt $17.91K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-09 | $17.91K S-3 · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |